Cancer - Alyssum Therapeutics Inc.

Cancer

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT06234098

A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PRELIMINARY ANTITUMOR ACTIVITY OF AT-1965 IN PATIENTS WITH ADVANCED, REFRACTORY OR RECURRENT SOLID TUMORS

Drug

AT-1965

Condition

PATIENTS WITH ADVANCED REFRACTORY OR RECURRENT SOLID TUMORS